Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
inclacumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Caucasian Healthy volunteers | ACTIVE_COMPARATOR | - |
| Japanese Healthy volunteers | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| inclacumab | DRUG | single intravenous doses |
Inclusion Criteria: * Healthy male and female volunteers, 18 to 55 years of age, inclusive Healthy status as defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination * Japanese subjects must have Japanese p...
Inclacumab is an investigational monoclonal antibody developed by Roche Holding AG (ticker RHHBY). It is a P-selectin antagonist that has been studied in Phase 1 clinical trials. It is not an approved medicine, and its clinical development remains at the early-stage Phase 1 level.
Inclacumab targets SELP, the gene encoding P-selectin, and acts as an antagonist of that target. By binding P-selectin, the monoclonal antibody is designed to block P-selectin mediated interactions. P-selectin is a cell adhesion molecule involved in the recruitment of leukocytes and platelets.
Inclacumab is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the clinical program for this monoclonal antibody. The asset is identified in public drug databases under the ChEMBL identifier CHEMBL2109488.
Inclacumab is in Phase 1 clinical development. It is an investigational monoclonal antibody and is not an approved product. The Phase 1 program has completed, with one trial recorded and no active trials at this time.
Inclacumab has been evaluated in the Phase 1 trial NCT01815827, titled A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers. That trial enrolled 62 healthy adult volunteers in the United States, used an active-controlled randomized design, and has completed.